Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
University of Michigan
Modality
radiopharmaceutical
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03396874CT.gov Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 68ga-psma (this asset) | University of Michigan | P2 | CCC · 54 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Prednisone | Mayo Clinic | P3 | BB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Bicalutamide | OHSU Knight Cancer Institute | P3 | BB |
| Leuporelin | Mayo Clinic | P3 | BB |
| Lidocaine | Bagcilar Training and Research Hospital | P4 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for 68ga-psma
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P2 | B · 59 |
| Metastatic Prostate Carcinoma | — | P2 | B · 57 |
| Melanoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 68ga-psma in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/68ga-psma-prostate-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →